NIH scientists identify two drug candidates for AMD treatment
Researchers at the US National Institutes of Health (NIH) unit National Eye Institute (NEI) have identified two potential drug candidates for age-related macular degeneration (AMD) treatment.
December 17, 2021
by Pharmaceutical-Technology
New Rapid Molecular COVID-19 Test from Anavasi Diagnostics Awarded $14.9 Million by NIH to Accelerate Test Availability
Anavasi Diagnostics, a medical technology company focused on the development of novel molecular diagnostic testing using a proprietary patent-pending reverse transcriptase methodology...
November 12, 2021
by AmericanPharmaceuticalReview
NIH study says repurposed cancer therapies beneficial for Alzheimer’s
Scientists from the US National Institutes of Health (NIH) unit National Institute on Aging (NIA) have found that present and developing therapies for cancer could potentially...
November 12, 2021
by Pharmaceutical-Technology
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
The U.S. Food and Drug Administration, the National Institutes of Health, 10 pharmaceutical companies and five non-profit organizations have partnered to accelerate development of gene therapies...
October 29, 2021
by WorldPharmaNews
Privo Technologies Awarded $3M NIDCR NIH Commercialization Readiness Pilot Grant
Privo Technologies, Inc. ("Privo") announced today that the National Institute of Dental and Craniofacial Research of NIH has awarded Privo approximately $3 million over three years in a Commercialization Readiness Pilot (CRP) grant as part of the SRIR.
August 24, 2021
by firstwordpharma
NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms
The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19.
August 19, 2021
by firstwordpharma
Monoclonal antibody prevents malaria in small NIH trial
One dose of a monoclonal antibody developed at the US National Institutes of Health (NIH) prevented malaria for up to nine months.
August 13, 2021
by europeanpharmaceuticalreview
NIH launches study of third COVID-19 vaccine dose in kidney transplant recipients
A pilot study has begun to assess the antibody response to a third dose of an authorised COVID-19 mRNA vaccine in kidney transplant recipients who did not respond to two doses of the Moderna or Pfizer-BioNTech COVID-19 vaccine.
August 12, 2021
by expresspharma
NIH trial closes enrolment for Brii Biosciences’ Covid-19 antibodies
Brii Biosciences has reported that the National Institutes of Health (NIH)’s ACTIV-2 clinical trial in the US completed enrolment for the Phase III part assessing its combination treatment, BRII-196 plus BRII-198, for Covid-19.
August 6, 2021
by pharmaceutical-technology
Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health ACTIV-4 trial in hospitalized patients with COVID-19.
June 30, 2021
by prnewswire
Fox Chase Researcher Receives NIH Grant to Advance Treatment of Immune Diseases Using Genome Editing
A Fox Chase Cancer Center researcher has received a grant of approximately half a million dollars from the National Institutes of Health (NIH) to identify disease-causing T cell defects.
June 29, 2021
by firstwordpharma
NIH Awards Vibrent Health Contract to Create a New Paradigm for Pandemic Preparedness and Response
The National Institutes of Health’s (NIH) National Cancer Institute (NCI) has awarded Vibrent Health, a digital health technology company powering the future of precision health research, the second phase of a contract to validate COVID-CARE ...
June 17, 2021
by americanpharmaceuticalreview